The role of prostanoid receptors in mediating the effects of PGE 3 on human platelet function

Thrombosis and Haemostasis

Volumn 107, Issue 4, 2012, Pages 797-799

  Iyú, David ^a   Glenn, Jackie R ^a   White, Ann E ^a   Johnson, Andrew ^a   Heptinstall, Stan ^a   Fox, Susan C ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; OMEGA 3 FATTY ACID; PADGEM PROTEIN; PROSTAGLANDIN E RECEPTOR 3; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROSTAGLANDIN E3; PROSTANOID RECEPTOR; THROMBOCYTE ACTIVATING FACTOR;

ANGIOGENESIS; HEART INFARCTION; HUMAN; LETTER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUDDEN DEATH; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOGENESIS;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ALPROSTADIL; ATHEROSCLEROSIS; BLOOD PLATELETS; CARDIOVASCULAR SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; P-SELECTIN; PLATELET ACTIVATING FACTOR; PLATELET AGGREGATION; RECEPTORS, PROSTAGLANDIN E;

EID: 84859317059     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-11-0794     Document Type: Letter

References (20)

1. Takai S, Jin D, Kawashima H, et al. Anti-atherosclerotic effects of dihomo-?-linolenic acid in ApoE-deficient mice. J Atheroscler Thromb 2009; 16: 480-489.
2. Gross S, Tilly P, Hentsch D, et al. Vascular wall-produced prostaglandin E2 exacerbates arterial thrombosis and atherothrombosis through platelet EP3 receptors. J Exp Med 2007; 204: 311-320.
3. Singh J, Zeller W, Zhou N, et al. Antagonists of the EP3 Receptor for prostaglandin E2 are novel antiplatelet agents that do not prolong bleeding. ACS Chem Biol 2009; 4: 115-126.
4. Madonna R, Salerni S, Schiavone D, et al. Omega-3 fatty acids attenuate constitutive and insulin-induced CD36 expression through a suppression of PPAR α/γ activity in microvascular endothelial cells. Thromb Haemost 2011; 106: 500-510.
5. Del Turco S, Basta G, Lazzarini G, et al. Parallel decrease of tissue factor surface exposure and increase of tissue factor microparticle release by the n-3 fatty acid docosahexaenoate in endothelial cells. Thromb Haemost 2007; 98: 219-219.
6. Szymczak M, Murray M, Petrovic N. Modulation of angiogenesis by?-3 polyunsaturated fatty acids is mediated by cyclooxygenases. Blood 2008; 111: 3514-3521.
7. Di Minno MND, Tremoli E, Tufano A, et al. Exploring newer cardioprotective strategies: ω-3 fatty acids in perspective. Thromb Haemost 2010; 104: 664-680.
8. Larson MK, Ashmore JH, Harris KA, et al. Effects of omega-3 acid ethyl esters and aspirin, alone and in combination, on platelet function in healthy subjects. Thromb Haemost 2008; 100: 634-641.
9. Gajos G, Rostoff P, Undas A, et al. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous intervention. J Am Coll Cardiol 2010; 55: 1671-1678.
10. De Caterina R. n-3 Fatty acids in cardiovascular disease. New Engl J Med 2011; 364: 2439-2450.
11. Moertl D, Berger R, Hammer A, et al. Dose-dependent decrease of platelet activation and tissue factor by omega-3 polyunsaturated fatty acids in patients with advanced chronic heart failure. Thromb Haemost 2011; 106: 500-510.
12. Holy EW, Forestier M, Richter EK, et al. Dietary alpha-linolenic acid inhibits arterial thrombus formation, tissue factor expression, and platelet activation. Arterioscler Thromb Vasc Biol 2011; 31: 1772-1780.
13. Fredman G, Van dyke TE, Serhan CN. Resolvin E1 regulates adenosine diphosphate activation of human platelets. Arterioscler Thromb Vasc Biol 2010; 30: 2005-2013.
14. Schmitz G, Ecker J. The opposing effects of n-3 and n-6 fatty acids. Progress in Lipid Res 2008; 47: 147-155.
15. Iyú D, Glenn JR, White AE, et al. The role of prostanoid receptors in mediating the effects of PGE2 on human platelet function. Platelets 2010; 21: 329-342.
16. Kuriyama S, Kashiwagi H, Yuhki KI, et al. Selective activation of the prostaglandin E2 receptor subtype EP2 or EP4 leads to inhibition of platelet aggregation. Thromb Haemost 2010; 104: 796-803.
17. Smith JP, Haddad EV, Downey JD, et al. PGE2 decreases reactivity of human platelets by activating EP2 and EP4. Thromb Res 2010; 126: 23-29.
18. Iyú D, Jüttner M, Glenn JR, et al. PGE1 and PGE2 modify platelet function through different prostanoid receptors. Prostaglandins Other Lipid Mediat 2011; 94: 9-16.
19. Heptinstall S, Espinosa DI, Manolopoulos P, et al. DG-041 inhibits the EP3 receptor-a new target for inhibition of platelet function in atherothrombotic disease. Platelets 2008; 19: 605-613.
20. Fabre JE, Gurney ME. Limitations of current therapies to prevent thrombosis: a need for novel strategies. Mol Bio Syst 2010; 6: 305-315.